- Home
- OFLX vs ERAS Comparison
OFLX vs ERAS Comparison
Compare OFLX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFLX
- ERAS
- Stock Information
- Founded
- OFLX 1975
- ERAS 2018
- Country
- OFLX United States
- ERAS United States
- Employees
- OFLX N/A
- ERAS N/A
- Industry
- OFLX Industrial Specialties
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- OFLX Industrials
- ERAS Health Care
- Exchange
- OFLX Nasdaq
- ERAS Nasdaq
- Market Cap
- OFLX 374.3M
- ERAS 432.6M
- IPO Year
- OFLX 2005
- ERAS 2021
- Fundamental
- Price
- OFLX $34.78
- ERAS $1.37
- Analyst Decision
- OFLX
- ERAS Strong Buy
- Analyst Count
- OFLX 0
- ERAS 6
- Target Price
- OFLX N/A
- ERAS $4.83
- AVG Volume (30 Days)
- OFLX 27.1K
- ERAS 1.8M
- Earning Date
- OFLX 03-05-2025
- ERAS 03-20-2025
- Dividend Yield
- OFLX 3.80%
- ERAS N/A
- EPS Growth
- OFLX N/A
- ERAS N/A
- EPS
- OFLX 1.78
- ERAS N/A
- Revenue
- OFLX $101,681,000.00
- ERAS N/A
- Revenue This Year
- OFLX N/A
- ERAS N/A
- Revenue Next Year
- OFLX N/A
- ERAS N/A
- P/E Ratio
- OFLX $19.81
- ERAS N/A
- Revenue Growth
- OFLX N/A
- ERAS N/A
- 52 Week Low
- OFLX $34.39
- ERAS $1.23
- 52 Week High
- OFLX $75.15
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- OFLX 32.75
- ERAS 39.36
- Support Level
- OFLX $37.36
- ERAS $1.40
- Resistance Level
- OFLX $39.64
- ERAS $1.61
- Average True Range (ATR)
- OFLX 1.40
- ERAS 0.11
- MACD
- OFLX -0.47
- ERAS 0.01
- Stochastic Oscillator
- OFLX 2.60
- ERAS 4.00
About OFLX Omega Flex Inc.
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.